In this video, Brenton Flynn describes Questcor Pharmaceuticals' primary opportunity. It's a drug called Acthar, a long acting gel that slowly releases a natural hormone called ACTH. Even though ACTH was approved 60 years ago, Questcor has seen sales of Acthar double this past year, with a projected earnings growth of 20% for the upcoming year. Selling at less than 7.5 times future earnings and paying a 3% dividend, Questcor looks like an attractive value stock.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 08/04/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return